AAI 101

Drug Profile

AAI 101

Alternative Names: AAI101

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allecra Therapeutics
  • Class Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urinary tract infections
  • Phase I Gram-negative infections

Most Recent Events

  • 04 Jul 2017 Phase-II clinical trials in Urinary tract infections (In adults, In the elderly) in Hungary (IV) (EudraCT2016-005161-31)
  • 26 May 2016 Phase-I development is ongoing in France
  • 08 Sep 2014 Pharmacokinetics and adverse events data from a phase I trial in healthy volunteers released by Allecra Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top